November 26, 2018 / 7:16 AM / 23 days ago

Vectura to stop developing asthma treatment after late-stage failure

Nov 26 (Reuters) - British drugmaker Vectura Group Plc said on Monday it would stop developing its treatment for severe uncontrolled asthma after the drug-device combination failed to meet the main goal of a late-stage study.

The move will result in a negative impact of 40 million pounds ($51.3 million) on Vectura’s loss before tax in the current financial year.

$1 = 0.7800 pounds Reporting by Noor Zainab Hussain in Bengaluru Editing by Sai Sachin Ravikumar

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below